DESIGNED TO FIT INTO EVERYDAY LIFE.

For Patients For Healthcare Professionals

DESIGNED TO FIT INTO EVERYDAY LIFE.

InSure® ONE™

InSure ONE is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples. The samples will generally be collected by the patient at home and the test developed at laboratories or professional offices. The InSure ONE test is used to aid in the detection of lower gastrointestinal bleeding.

When to use InSure ONE?

The American Cancer Society (ACS) recommends both men and women at average risk for developing colorectal cancer (CRC) beginning screening at age 50.

InSure ONE is a highly accurate test for detecting blood in fecal samples, which may be an indication of lower gastrointestinal bleeding associated with disorders such as diverticulitis, ulcerative colitis, polyps, colorectal cancers or large adenomas that bleed.

Why use InSure ONE?

InSure ONE is the only FIT that is performed using toilet water collected from a single bowel movement.

  • The InSure ONE test is easier to use. To get a reliable sample, patients only need to gently brush the surface of the stool in water for about 5 seconds with the convenient, long-handled blue brush.
  • No other in-home test has this convenient, water-based collection method – if you have used a paintbrush, you can use the InSure ONE test.
  • There are no diet or medication restrictions associated with using InSure ONE.
  • With the InSure ONE test, samples are collected in the privacy of your home, then submitted to your doctor’s office or laboratory for analysis.

The InSure ONE test is available from your doctor. The Patient Collection Kit contains everything you need to collect and submit test samples for analysis.

Colorectal cancer screening guidelines

Fecal immunochemical tests are recommended by medical guidelines for use in colorectal cancer screening programs and are recognized as being highly effective when repeated annually.

  • FIT is supported by medical guidelines, including The American Cancer Society, The American College of Gastroenterology and the USPSTF, for use in colorectal cancer screening programs.
  • The U.S. Multi-Society Task Force for Colorectal Cancer recommends colorectal cancer (CRC) screening begin at age 50 years in asymptomatic persons, with colonoscopy every 10 years or FIT annually as first option, Tier 1 tests for screening for colorectal neoplasia. Download Guidelines Summary PDF

About colorectal cancer

Colorectal cancer is the third most common cancer diagnosed, and the second leading cause of cancer related deaths in both men and women in the United States. This year, an estimated 140,000 people will be diagnosed with CRC, with approximately 50,000 people succumbing to the disease.2

Risk Factors:

  • Men and women age 45 and older
  • Family history of colon cancer
  • History of colon or rectal polyps
  • Inflammatory bowel disease (Crohn’s or ulcerative colitis)
  • Familial adenomatous polyposis (FAP)
  • Hereditary non-polyposis colon cancer
  • Obesity
  • Smoking
  • Heavy alcohol use
  • Racial and ethnic background
  • Men and women age 50 and older
  • Family history of colon cancer
  • History of colon or rectal polyps
  • Inflammatory bowel disease (Crohn’s or ulcerative colitis)
  • Familial adenomatous polyposis (FAP)
  • Hereditary non-polyposis colon cancer
  • Obesity
  • Smoking
  • Heavy alcohol use
  • Racial and ethnic background

Social Icons

Facebook Twitter LinkedIn

Copyright © 2018 Clinical Genomics Technologies Pty Ltd. All Rights Reserved.